TY - JOUR T1 - Continuing alendronate for an additional 5 years maintained bone mineral density in postmenopausal women JF - Evidence Based Medicine JO - Evid Based Med SP - 70 LP - 70 DO - 10.1136/ebm.12.3.70 VL - 12 IS - 3 A2 - , Y1 - 2007/06/01 UR - http://ebm.bmj.com/content/12/3/70.abstract N2 - Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA 2006;296:2927–38.OpenUrlCrossRefPubMedWeb of Science 
 
 Q In postmenopausal women with low bone mineral density (BMD) who had been receiving daily alendronate for a mean of 5 years, what is the effect of continuing alendronate treatment for 5 years compared with discontinuing it? Clinical impact ratings GP/FP/Primary care ★★★★★★☆ Endocrine ★★★★★★☆ Rheumatology ★★★★★★☆ Internal medicine ★★★★★☆☆ Surgery—orthopaedics ★★★★★☆☆ Design: randomised placebo controlled trial (Fracture Intervention Trial [FIT] Long-term Extension [FLEX]). Allocation: unclear allocation concealment.* Blinding: blinded (clinicians, participants, data collectors, and outcome assessors).* Follow up period: 5 years. Setting: 10 clinical centres in the US. Patients: 1099 postmenopausal women (mean age 73 y, 97% white) who had had low femoral neck BMD (<0.68 g/cm2) and had been allocated to alendronate (5 mg/d for 2 y and 10 … ER -